

## Special Issue

# Precision Medicine and Molecular Diagnosis for Urogenital Cancer

### Message from the Guest Editors

Urogenital cancers include tumours of the kidney and bladder, and, in men, of the prostate and testicle pose considerable challenges to the urologist. Recent advances in molecular diagnosis and precision medicine provide more therapeutic strategies and favourable prognoses in patients with urogenital cancers. This Special Issue of the *Journal of Personalized Medicine* aims to explore the latest innovative molecular findings or clinical experience to provide more evidence to support further clinical trials. Studies of basic science, translational, clinical and population-based approaches are encouraged to submit contributions. Our goal is to demonstrate the scientific advances in the field of urogenital cancers and pave the way towards personalized medicine or diagnosis. Both original research and review articles are welcome.

---

### Guest Editors

Dr. Wen-Wei Sung

Dr. Jian-Ri Li

Dr. Chih-Jung Chen

Dr. Cheng-Kuang Yang

---

### Deadline for manuscript submissions

closed (10 June 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/104570](https://mdpi.com/si/104570)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).